Complete response to pembrolizumab in a patient with dermatomyositis and MMR deficient ovarian cancer: A case report

• Immune checkpoint inhibitors can be safely administered to patients with dermatomyositis. • Immunosuppressants did not impact the efficacy of treatment with an immune check point inhibitor. • Patients with autoimmune disorders who require immune check point inhibitors should be monitored by a rheu...

Descripción completa

Detalles Bibliográficos
Autores principales: Valls, Maia L., Kase, Adam M., Patel, Rina, Wang, Benjamin, Aggarwal, Rohit, Colon-Otero, Gerardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9156981/
https://www.ncbi.nlm.nih.gov/pubmed/35663849
http://dx.doi.org/10.1016/j.gore.2022.101010
Descripción
Sumario:• Immune checkpoint inhibitors can be safely administered to patients with dermatomyositis. • Immunosuppressants did not impact the efficacy of treatment with an immune check point inhibitor. • Patients with autoimmune disorders who require immune check point inhibitors should be monitored by a rheumatologist.

Ejemplares similares